2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Cisplatin
161
Fluorouracil
135
Paclitaxel
127
Radiotherapy
125
Oxaliplatin
88
Carboplatin
72
Docetaxel
71
Irinotecan
60
pembrolizumab
57
Leucovorin
57
Capecitabine
57
Radiation
48
Esophagectomy
44
Surgical Procedures, Operative
42
Drug Therapy
38
Neoadjuvant Therapy
28
Cetuximab
25
Nivolumab
24
Bevacizumab
21
camrelizumab
20
Trastuzumab
20
S 1 (combination)
19
Chemoradiotherapy
19
Magnetic Resonance Spectroscopy
18
Epirubicin
16
Albumin-Bound Paclitaxel
16
Blood Specimen Collection
15
tislelizumab
14
Taxes
14
Radiotherapy, Intensity-Modulated
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
zimberelimab
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled